Q4 2025 Quanterix Corp Earnings Call Transcript
Key Points
- Quanterix Corp (QTRX) reported a 25% increase in total revenue for Q4 2025, reaching $43.9 million, indicating strong financial performance.
- The company has a solid balance sheet with over $100 million in cash and no debt, providing financial stability.
- Quanterix Corp (QTRX) achieved significant milestones with its Lucent AD complete test, including a CMS-approved reimbursement rate of $897 and a 510(k) premarket notification submission to the FDA.
- The company launched 13 new assays in 2025, demonstrating a strong innovation pipeline and commitment to product development.
- Quanterix Corp (QTRX) is on track to achieve $85 million in cost synergies by the end of Q1 2026, which will support its goal of reaching cash flow breakeven in the second half of the year.
- Organic revenue declined by 22% year-over-year, indicating challenges in maintaining growth in core business areas.
- Revenue from the spatial segment decreased by 23% year-over-year, highlighting potential issues in this business line.
- The terminated diagnostics development agreement negatively impacted spatial revenues, which were down 16% year-over-year excluding the agreement.
- Pharma revenue declined by 21% year-over-year, primarily due to lower large accelerator projects compared to the prior year.
- The company reported an adjusted EBITDA loss of $7.9 million for Q4 2025, although this was an improvement from the previous quarter.
Ladies and gentlemen, thank you for standing by. My name is Colby, and I will be your conference operator today. At this time, I would like to welcome you to the Quanterix Corporation Q4 2025 earnings call. (Operator Instructions) I will now turn the call over to Joshua Young. You may begin.
Thank you, Colby, and good afternoon, everybody. With me on today's call are Everett Cunningham, Quanterix President and CEO and Vandana Sriram, Quanterix Chief Financial Officer. Today's call is being recorded, and a replay of the call will be available on the Investor Relations section of our website.
During the course of today's presentation, we will make forward-looking statements within the meaning of the US Private Securities Litigation Reform Act. These forward-looking statements are based on management's beliefs and assumptions as of today, March 2, 2026. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements.
Forward-looking statements involve
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
